Market-Ready Meds Could Slow Dementia, Panel Finds
An international expert panel identifies eight drugs already on the market as candidates for further study to prevent or slow dementia. The shingles vaccine shows the strongest real‑world signal, with Welsh data suggesting about a 20% reduction in dementia risk among recipients; the newer Shingrix vaccine is anticipated to be at least as effective. Other drugs cited include Viagra (sildenafil), riluzole, Gilenya (fingolimod), and vortioxetine, though evidence for these is less clear and confounded by factors such as lifestyle and relationships. The panel emphasizes more rigorous research and potential trials to determine true benefits at the population level.
